Activation of the IL-17/MAPK signaling pathway can lead to an increase in immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells (MDSCs), thereby inhibiting the anti-tumor immune response. This evidence concerns the gene IL17A and neoplasm.